Birth defects monitoring.
Population monitoring of birth defects provides a means for detecting relative changes in their frequency. Many varied systems have been developed throughout the world since the thalidomide tragedy of the early 1960s. Although it is difficult to pinpoint specific teratogenic agents based on rises in rates of a particular defect or a constellation of defects, monitoring systems can provide clues for hypothesis testing in epidemiological investigations. International coordination of efforts in this area resulted in the founding of the International Clearinghouse for Birth Defects Monitoring Systems (ICBDMS) in 1974. In this paper we will describe the functions and basic requirements of monitoring systems in general, and look at the development and activities of the ICBDMS. A review of known and suspected environmental teratogenic agents (eg, chemical, habitual, biological, physical, and nutritional) is also presented.
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000016:Abnormalities, Radiation-Induced / Q000453:epidemiology; D000777:Anesthetics / Q000633:toxicity; D000927:Anticonvulsants / Q000633:toxicity; D000932:Antiemetics / Q000633:toxicity; D000995:Antitubercular Agents / Q000633:toxicity; D001424:Bacterial Infections / Q000150:complications; D000013:Congenital Abnormalities / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005494:Folic Acid Deficiency / Q000150:complications; D012739:Gonadal Steroid Hormones / Q000633:toxicity; D014645:Herpesvirus 3, Human / Q000472:pathogenicity; D006634:Histamine H1 Antagonists / Q000633:toxicity; D006801:Humans; D007114:Immunization / Q000009:adverse effects; D010575:Pesticides / Q000633:toxicity; D011247:Pregnancy; D012412:Rubella virus / Q000472:pathogenicity
D000777:Anesthetics; D000927:Anticonvulsants; D000932:Antiemetics; D000995:Antitubercular Agents; D012739:Gonadal Steroid Hormones; D006634:Histamine H1 Antagonists; D010575:Pesticides